# Low Antimonial Dosage in American Mucosal Leishmaniasis

> **NCT01301937** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Oswaldo Cruz Foundation** · enrollment: 76 (estimated)

## Conditions studied

- Mucosal Leishmaniasis
- Mucocutaneous Leishmaniasis

## Interventions

- **DRUG:** Meglumine antimoniate

## Key facts

- **NCT ID:** NCT01301937
- **Lead sponsor:** Oswaldo Cruz Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-10
- **Primary completion:** 2020-12
- **Final completion:** 2021-12
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2018-07-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01301937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01301937, "Low Antimonial Dosage in American Mucosal Leishmaniasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01301937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*